beta

ALLK

Allakos, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.

Market Cap: 5.89 Billion

Primary Exchange: NASDAQ

Website: http://www.allakos.com

Shares Outstanding: 48.7 Million

Float: 22.4 Million

Dividend: (%)

Beta: -0.426627829586913

Sector: Health Technology

Industry: Pharmaceuticals: Major

Ethical Flags

Longest drawdown: 946 trading days

From: 2018-12-10 To: 2019-08-02

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud